Name | Manitimus |
---|---|
Synonyms |
2-Hepten-6-ynamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-, (2Z)-
(2Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-hepten-6-ynamide Manitimus 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide |
Description | Manitimus is an inhibitor of dehydroorotate dehydrogenase, and a potent immunosuppressive drug. |
---|---|
Related Catalog | |
In Vivo | In the Manitimus-treated rats, there is a dose-related, differential effect: mean survival is 15.7 days in group 4 (Manitimus 5 mg/kg), 19.1 days in group 5 (Manitimus 10 mg/kg) and 25.4 days in group 6 (Manitimus 20 mg/kg)[1]. Manitimus (15 mg/kg, p.o.) results in a significant decrease in neointimal area and percentage of stenosis versus the control rats, and diminishes the effect that CMV infection results in a significant increase in intimal and medial cross-sectional area and medial wall thickness of the vein grafts[2]. |
Animal Admin | The whole experiment consists of a total of four experimental groups (n = 10 animals/group) which all undergo surgery. Furthermore, rats are either infected with CMV, treated with Manitimusor both. A control group only receive the Manitimus solvent (1 mL of a 1% carboxymethylcellulose solution in water). Infection is established by inoculating rats intraperitoneally with 1.25×106 plaque-forming units of homogenized salivary gland-derived rat CMV immediately after surgery. |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 489.4±45.0 °C at 760 mmHg |
Molecular Formula | C15H11F3N2O2 |
Molecular Weight | 308.255 |
Flash Point | 249.8±28.7 °C |
Exact Mass | 308.077271 |
LogP | 3.49 |
Vapour Pressure | 0.0±1.3 mmHg at 25°C |
Index of Refraction | 1.562 |
Storage condition | 2-8℃ |